EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Inhibition of Nitric Oxide Synthase by L-NAME Promotes Cisplatin-Induced Nephrotoxicity in Male Rats

Fatemeh Moslemi, Mehdi Nematbakhsh, Fatemeh Eshraghi-Jazi, Ardeshir Talebi, Hamid Nasri, Farzaneh Ashrafi, Maryam Moeini, Azam Mansouri, Zahra Pezeshki

ISRN Toxicology · 2013

DOI: 10.1155/2013/242345 ↗
AbstractBibliografische Angaben

Abstract

Objective . Nitric oxide (NO) has numerous important functions in the kidney. The role of NO in cisplatin (CP)-induced nephrotoxicity is not completely understood. This study was designed to determine the role of NO synthase inhibitor (L-NAME) on the severity of CP-induced nephrotoxicity in rats. Methods . Sixty four male (M) and female (F) Wistar rats were randomly divided into eight groups. The sham groups (group 1, male, n = 6 and group 2, female, n = 6 ) received saline. Groups 3 (male, n = 8 ) and 4 (female, n = 8 ) were treated with L-NAME (4 mg/kg, i.p.), and groups 5 (male, n = 8 ) and 6 (female, n = 8 ) received CP (3 mg/kg) for 7 days. Groups 7 (male, n = 8 ) and 8 (female, n = 8 ) were treated with L-NAME and CP for 7 days. Results . The CP-alone treated rats showed weight loss and increase in serum levels of blood urea nitrogen (BUN) and creatinine (Cr). Coadministration of L-NAME and CP did not improve weight loss, and it increased the levels of BUN and Cr in male but not in female rats ( P < 0.05 ). CP alone increased kidney damage significantly ( P < 0.05 ), however, the damage induced by combination of CP and L-NAME was gender-related. Conclusion . NOS inhibition by L-NAME increased CP-induced nephrotoxicity, which was gender-related.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →